Publication on Dec. 12, 2024, of data analysis regarding Merck & Co. Inc.’s Winrevair (sotatercept) in Clinical Pharmacology & Therapeutics may have put investors in mind of the odds for the activin ...
Welcome to Fierce Pharma's regulatory tracker for the first half of 2025. | In this tracker, Fierce Pharma is recording the ...
Merck Sharp & Dohme’s sotatercept gets UK MHRA marketing approval to treat adult patients with pulmonary arterial hypertension: United Kingdom Friday, January 3, 2025, 17:00 Hrs ...
Merck's Winrevair (sotatercept) gains UK approval for PAH treatment. Key trial results highlight significant exercise ...
MSD has received the UK Medicines and Healthcare products Regulatory Agency (MHRA) approval for sotatercept, marketed as ...
Regulators squeezed in two final approvals before the calendar change with the UK approval of Merck’s Winrevair and the FDA’s ...
Stocktwits on MSN5d
Merck Stock In Focus After Regulatory Approval For PAH Drug: Retail Sentiment BrightensShares of Merck & Co. Inc ($MRK) were in the spotlight this week after the pharmaceutical major secured regulatory approval ...
Merck has received approval from the UK's Medicines and Healthcare products Regulatory Agency for its therapy, sotatercept, ...
UK's Medicines and Healthcare products Regulatory Agency said on Tuesday it had approved Merck's therapy to treat a rare lung ...
Merck (NYSE:MRK) has received approval from the U.K.'s Medicines and Healthcare products Regulatory Agency for its drug ...
The Medicines and Healthcare products Regulatory Agency of the United Kingdom announced has approved the medicine sotatercept, Winrevair, to ...
The UK Medicines and Healthcare products Regulatory Agency (MHRA) has approved Winrevair (sotatercept) to treat pulmonary ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback